SCHEMBL5361802

SCHEMBL5361802

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1sccc1C)C(=O)N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 14/20 0.54
CDK2 P24941 2/20 0.52
KDR P35968 9/20 0.51
LCK P06239 8/20 0.49
FYN P06241 8/20 0.49
YES1 P07947 8/20 0.49
FGFR1 P11362 8/20 0.49
PDGFRB P09619 7/20 0.49
NTRK1 P04629 1/20 0.49
FCER2 P06734 1/20 0.49
SYK P43405 1/20 0.49
NTRK3 Q16288 1/20 0.49
NTRK2 Q16620 1/20 0.49
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
AURKA O14965 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364548 0.88 KDR (0.59) SRCCDK2KDRLCKFYN
SCHEMBL5361719 0.87 PDPK1 (0.58) SRCCDK2KDRFGFR1PDGFRB
SCHEMBL5368785 0.82 MOGAT2 (0.55) MEN1MAPTKMT2APDPK1
SCHEMBL7130537 0.81 MEN1 (0.58) SRCCDK2KDRLCKFYN
SCHEMBL5363755 0.81 PDPK1 (0.66) SRCCDK2KDRLCKFYN
SCHEMBL5368868 0.81 SRC (0.49) SRCCDK2KDRLCKFYN
SCHEMBL5376707 0.80 PDPK1 (0.68) KDRNTRK1MEN1NPC1ALDH1A1
SCHEMBL5359785 0.80 SRC (0.54) SRCCDK2KDRLCKFYN
SCHEMBL7138258 0.80 MEN1 (0.66) SRCCDK2KDRLCKFYN
SCHEMBL7136883 0.79 SRC (0.58) SRCCDK2KDRLCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK SRC 189/4885CDK2 256/4885KDR 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.